Factor_IX: profile and news

Biosante wins $250,000 research contract Feb 22, 2006
...has been awarded a $250,000 (€210,000) subcontract from the University of Nebraska, Lincoln (UNL), to develop recombinant Factor IX (FIX) formulations for ... - In-PharmaTechnologist.com,

3rd Generation Andretti Will Race at Indianapolis 500 to Support ... Feb 22, 2006
...is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX. Bayer HealthCare, a subgroup ... - Genetic Engineering News,

Premier's New Plasma and Recombinant Program Helps Hospitals ... Feb 26, 2006
...include albumin; intravenous immunoglobulin (IVIG); hyperimmune globulin; various coagulation factor products including Factor VIII and Factor IX; alpha-1 ... - dBusinessNews Charlotte (press release),

Research Highlights Feb 22, 2006
Children's Hospital of Philadelphia, Pennsylvania, and her team injected sufferers with a modified virus carrying the gene for blood coagulation factor IX (F.IX ... - Nature.com (subscription),

BioSante Pharmaceuticals Announces Subcontract with the University ... Feb 6, 2006
...(AMEX:BPA) today announced that BioSante has been awarded a subcontract valued at $250,000 for the development of recombinant Factor IX (FIX) formulations for ... - Genetic Engineering News,

Other information

Indication
For treatment of hemophilia (Christmas diseae)

Pharmacology
Binds vitamin K and factor VIIIa. Cleaves the Arg-Ile bond in factor X to form active factor Xa. Plays a key role in blood coagulation and clotting. Injections of factor IX are used to treat hemophilia B, which is sometimes called Christmas disease. AlphaNine is injected to increase plasma levels of Factor IX and can temporarily correct this coagulation defect.

Mechanism Of Action
Cleaves the Arg-Ile bond in Factor X to form active factor Xa leading to coagulation and clotting.

Drug Category
Coagulants; Thrombotic Agents; hemostatics (20:12.16)

Brand Names/Synonyms
Coagulation factor IX precursor;Christmas factor;Plasma thromboplastin component;PTC; Benefix (Genetics Institute)

Dosage Forms
LIQUID;POWDER FOR SOLUTION

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Human factor IX protein

Chemical Formula
C2041H3136N558O641S25

Half Life
17 to 32 hrs

Drug Type
Approved Drug

# Accession No
BIOD00038

CAS Registry Number
9001-28-9